Crown Bioscience

Crown Bioscience

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research.

Telephone: 0870 166 6234
Address: Hillcrest, Dodgeford Lane, Belton, Loughborough
Postcode: LE12 9TE
Country: United Kingdom
Website: http://www.crownbio.com
Membership type:Corporate 51+ (£1,000+VAT pa)

. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.

Crown Bioscience publishes new pancreatic ductal adenocarcinoma research

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has recently published in the Journal of Visual Experiments the establishment and immunological characterization of PDAC orthotopic tumour homograft models.

19 November 2018Read in full

Crown Bioscience showcases scientific expertise at the EORTC-NCI-AACR

Crown Bioscience releases new model data, including Prostate Cancer PDX and humanised target models for the evaluation of combination human checkpoint inhibitors.

12 November 2018Read in full

Crown Bioscience expands cardiovascular & metabolic disease research capability

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced the expansion of its New Iberia, Louisiana research facilities to support novel capabilities including non-GLP clinical chemistry, biomarker services and proprietary early stage preclinical models.

12 November 2018Read in full

MuBase magnifying glass look at a bar chart

CrownBio releases open access database of immuno-oncology murine models

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has released MuBase 2.0.

30 October 2018Read in full

CrownBio completes validation of prostate cancer patient-derived xenograft (PDX) models

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced the addition of unique, well characterized, fully annotated patient-derived xenograft (PDX) models of prostate cancer.

1 October 2018Read in full

CARsgen Therapeutics and CrownBio complete CAR-T study for gastric cancer

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has completed a joint study with CARsgen Therapeutics and Shanghai Cancer Institute, demonstrating the elimination of gastric tumors in mice using CLDN18.2 targeting CAR-T cells.

17 September 2018Read in full

CrownBio expands genetically engineered model selection via strategic alliance

CrownBio's alliance with Shanghai Model Organisms Center (SMOC) enables researchers to access thousands of GEMMs.

15 August 2018Read in full

CrownBio partners with Pierre Fabre to accelerate discovery of immuno-oncology agents

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.

22 June 2018Read in full

CrownBio demonstrates advantages of innovative translational oncology platform

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, publishes scientific posters with dynamic audio narration.

11 May 2018Read in full

CrownBio launches new humanised target model for immunotherapy

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanised drug target models (HuGEMMâ„¢) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs.

30 April 2018Read in full

  1. 1
  2. 2